Friday, October 28, 2016
Oventus Medical Ltd is proud to announce it has entered into a collaboration agreement with 1300SMILES Ltd.
This collaboration allows 1300SMILES’s dentists to provide treatment for snoring and obstructive sleep apnoea (OSA) sufferers with the use of Oventus products.
Managing Director of 1300SMILES, Dr Daryl Holmes, said “We are very excited about this new arrangement, which allows our Dentists and Practices to provide this innovative, lifechanging product and service to our patients. This increases the scope and range of services we offer and hence revenue streams and profitability for our group.”
Incredibly, more than 800,000 Australians suffer from obstructive sleep apnoea (OSA) ¹, whilst the global sleep disordered breathing market is estimated to be worth $50 billion annually.
The device, which was created by Brisbane dentist Dr Chris Hart, who founded Oventus and is the company’s Clinical Director, is indicated for use during sleep to aid in the treatment of snoring and OSA.
A clinical study completed earlier this year showed the company’s first generation product the O2VENT MonoTM is successful in treating OSA and that snoring was either eliminated or significantly reduced in 100 per cent of patients . The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep.
Oventus Managing Director and Chief Executive Officer, Neil Anderson said “We are delighted to be working with a professional and well established dental corporate partner, and look forward to a mutually beneficial collaboration. This collaboration provides us with direct access to the 1300SMILES group of clinicians and will ultimately allow more patients with obstructive sleep apnoea to be brought into care.”
Source : oventusmedicalinvestors.com
